Literature DB >> 25854704

Parathyroid hormone: anabolic and catabolic actions on the skeleton.

Barbara C Silva1, John P Bilezikian2.   

Abstract

Parathyroid hormone (PTH) is essential for the maintenance of calcium homeostasis through, in part, its actions to regulate bone remodeling. While PTH stimulates both bone formation and bone resorption, the duration and periodicity of exposure to PTH governs the net effect on bone mass, that is whether it is catabolic or anabolic. PTH receptor signaling in osteoblasts and osteocytes can increase the RANKL/OPG ratio, increasing both osteoclast recruitment and osteoclast activity, and thereby stimulating bone resorption. In contrast, PTH-induced bone formation is explained, at least in part, by its ability to downregulate SOST/sclerostin expression in osteocytes, permitting the anabolic Wnt signaling pathway to proceed. The two modes of administration of PTH, that is, continuous vs. intermittent, can regulate, in bone cells, different sets of genes; alternatively, the same sets of genes exposed to PTH in sustained vs. transient way, will favor bone resorption or bone formation, respectively. This article reviews the effects of PTH on bone cells that lead to these dual catabolic and anabolic actions on the skeleton.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25854704      PMCID: PMC5407089          DOI: 10.1016/j.coph.2015.03.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  127 in total

Review 1.  Calcium and phosphate homeostasis: concerted interplay of new regulators.

Authors:  R Civitelli; K Ziambaras
Journal:  J Endocrinol Invest       Date:  2011-07       Impact factor: 4.256

2.  Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.

Authors:  S K Lee; J A Lorenzo
Journal:  Endocrinology       Date:  1999-08       Impact factor: 4.736

3.  Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

Authors:  Faryal S Mirza; I Desmond Padhi; Lawrence G Raisz; Joseph A Lorenzo
Journal:  J Clin Endocrinol Metab       Date:  2010-02-15       Impact factor: 5.958

4.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

5.  Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.

Authors:  Yumie Rhee; Eun-Young Lee; Virginia Lezcano; Ana C Ronda; Keith W Condon; Matthew R Allen; Lilian I Plotkin; Teresita Bellido
Journal:  J Biol Chem       Date:  2013-08-20       Impact factor: 5.157

6.  Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.

Authors:  Qiang Fu; Robert L Jilka; Stavros C Manolagas; Charles A O'Brien
Journal:  J Biol Chem       Date:  2002-10-02       Impact factor: 5.157

7.  Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.

Authors:  Xiaodong Li; Michael S Ominsky; Qing-Tian Niu; Ning Sun; Betsy Daugherty; Diane D'Agostin; Carole Kurahara; Yongming Gao; Jin Cao; Jianhua Gong; Frank Asuncion; Mauricio Barrero; Kelly Warmington; Denise Dwyer; Marina Stolina; Sean Morony; Ildiko Sarosi; Paul J Kostenuik; David L Lacey; W Scott Simonet; Hua Zhu Ke; Chris Paszty
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

8.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

9.  Lrp5 functions in bone to regulate bone mass.

Authors:  Yajun Cui; Paul J Niziolek; Bryan T MacDonald; Cassandra R Zylstra; Natalia Alenina; Daniel R Robinson; Zhendong Zhong; Susann Matthes; Christina M Jacobsen; Ronald A Conlon; Robert Brommage; Qingyun Liu; Faika Mseeh; David R Powell; Qi M Yang; Brian Zambrowicz; Han Gerrits; Jan A Gossen; Xi He; Michael Bader; Bart O Williams; Matthew L Warman; Alexander G Robling
Journal:  Nat Med       Date:  2011-05-22       Impact factor: 53.440

10.  Control of bone mass and remodeling by PTH receptor signaling in osteocytes.

Authors:  Charles A O'Brien; Lilian I Plotkin; Carlo Galli; Joseph J Goellner; Arancha R Gortazar; Matthew R Allen; Alexander G Robling; Mary Bouxsein; Ernestina Schipani; Charles H Turner; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Teresita Bellido
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

View more
  113 in total

Review 1.  Efficacy of parathyroid hormone supplementation on the osseointegration of implants: a systematic review.

Authors:  Fawad Javed; Mohammad D Al Amri; Sergio Varela Kellesarian; Abdulaziz A Al-Kheraif; Fahim Vohra; José Luis Calvo-Guirado; Hans Malmstrom; Georgios E Romanos
Journal:  Clin Oral Investig       Date:  2015-12-22       Impact factor: 3.573

Review 2.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 3.  The role of vitamin D in the endocrinology controlling calcium homeostasis.

Authors:  James C Fleet
Journal:  Mol Cell Endocrinol       Date:  2017-04-09       Impact factor: 4.102

Review 4.  Systematic review of oral manifestations related to hyperparathyroidism.

Authors:  Benjamin Palla; Egon Burian; Riham Fliefel; Sven Otto
Journal:  Clin Oral Investig       Date:  2017-06-14       Impact factor: 3.573

5.  Parathyroid hormone-induced down-regulation of miR-532-5p for matrix metalloproteinase-13 expression in rat osteoblasts.

Authors:  Vishal Mohanakrishnan; Arumugam Balasubramanian; Gokulnath Mahalingam; Nicola Chennell Partridge; Ilangovan Ramachandran; Nagarajan Selvamurugan
Journal:  J Cell Biochem       Date:  2018-04-06       Impact factor: 4.429

6.  MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.

Authors:  Jesus Delgado-Calle; Benjamin Hancock; Elive F Likine; Amy Y Sato; Kevin McAndrews; Carolina Sanudo; Angela Bruzzaniti; Jose A Riancho; James R Tonra; Teresita Bellido
Journal:  FASEB J       Date:  2018-01-17       Impact factor: 5.191

7.  Loss of Gsα in osteocytes leads to osteopenia due to sclerostin induced suppression of osteoblast activity.

Authors:  Keertik Fulzele; Christopher Dedic; Forest Lai; Mary Bouxsein; Sutada Lotinun; Roland Baron; Paola Divieti Pajevic
Journal:  Bone       Date:  2018-09-25       Impact factor: 4.398

8.  Loss of Nmp4 optimizes osteogenic metabolism and secretion to enhance bone quality.

Authors:  Yu Shao; Emily Wichern; Paul J Childress; Michele Adaway; Jagannath Misra; Angela Klunk; David B Burr; Ronald C Wek; Amber L Mosley; Yunlong Liu; Alexander G Robling; Nickolay Brustovetsky; James Hamilton; Kylie Jacobs; Deepak Vashishth; Keith R Stayrook; Matthew R Allen; Joseph M Wallace; Joseph P Bidwell
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-01-15       Impact factor: 4.310

9.  Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass.

Authors:  Zhongbo Liu; Tianzhen Han; Haim Werner; Clifford J Rosen; Mitchell B Schaffler; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2017-11-06       Impact factor: 6.741

Review 10.  Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management.

Authors:  Jorge B Cannata-Andía; Beatriz Martín-Carro; Julia Martín-Vírgala; Javier Rodríguez-Carrio; José Joaquín Bande-Fernández; Cristina Alonso-Montes; Natalia Carrillo-López
Journal:  Calcif Tissue Int       Date:  2020-11-15       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.